Pharvaris N.V. Ordinary Shares
PHVS
Closed
$30.72
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 129 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Key stats
Open
$32.33
Volume
180.21K
Market cap
$2.48B
Prev. close
$30.72
Impl / hst vl
-
Open interest
$0.00
$30.60
Day’s Range
$33.29
$23.62
52W Range
$33.33
Valuation
33
Valuation score
Overvalued
P/E
-
P/S
-
P/B
6.76
Current ratio
11.24
Debt / Equity
-1.04
ROE
-67.14%
Gross margin
-
Income growth
-16.13%
FCF growth
28.62
Analysts estimates
Consensus rating
Strong buy
The average rating from top 9 analysts indicates that stock may significantly outperform the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$47.50
The top 16 analysts forecasts that 12-month price may increase by 54.63%, with a low of $33.33 and a high of $77.70
$33.33
Low
$47.50
Avg
$77.70
High
Current price
Earnings
Q1 ‘26 revenue
$0.00
Q1 ‘26 net income
-$45.34M
Revenue
Net income
Previous EPS
-$0.83
Estimate EPS
-$0.84
Actual EPS
Estimate EPS
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply